Introduction to Neurogenetics
5 sections · 20 min
What is Neurogenetics?
Neurogenetics is the study of how genetic variation — inherited or arising de novo — contributes to neurological disease. As a clinical discipline it bridges neurology and medical genetics, encompassing diagnosis, genetic counseling, and an increasingly robust landscape of mechanism-targeted therapies. The importance of neurogenetics has grown dramatically with next-generation sequencing: roughly 50% of pediatric-onset epilepsies, 30–40% of childhood intellectual disabilities, and a significant fraction of early-onset movement disorders and neurodegenerative diseases now have identifiable genetic causes.
Key Points
- Neurogenetics encompasses monogenic ('single-gene') disorders, chromosomal disorders, and complex polygenic traits with neurological manifestations
- Approximately 60% of known single-gene disorders have a neurological component — the nervous system is the most commonly affected organ system in Mendelian disease
- Genetic diagnosis enables: recurrence risk counseling, cascade testing of at-risk family members, and access to mechanism-targeted therapies
- The field spans lifespan: neonatal epileptic encephalopathies, childhood neurodevelopmental disorders, adult-onset movement disorders, and late-onset dementias
✦ Check Your Understanding
A 3-year-old boy presents with global developmental delay, no family history, and no distinctive features. Chromosomal microarray and fragile X testing are normal. What is the most appropriate next step?
Select an answer to reveal the explanation
Genetic Architecture of Neurological Disease
Neurological diseases span a continuum of genetic architecture: from fully penetrant Mendelian single-gene disorders to complex polygenic traits modulated by environmental exposures. Understanding which architecture applies to a given condition guides testing strategy, interpretation, and counseling. Most severe early-onset neurological conditions have a monogenic basis; common late-onset conditions (Alzheimer disease, Parkinson disease) are predominantly polygenic with rare high-penetrance variants in a subset of patients.
Key Points
- Monogenic (Mendelian): Single gene, high penetrance — e.g., Huntington disease (HTT CAG repeat, autosomal dominant), Duchenne muscular dystrophy (DMD, X-linked recessive), Friedreich ataxia (FXN GAA repeat, autosomal recessive)
- Chromosomal: Gain or loss of large genomic segments — e.g., Down syndrome (trisomy 21), 22q11.2 deletion syndrome, 15q11–q13 imprinting disorders
- De novo variants: Arise spontaneously in the germline; disproportionately responsible for severe early-onset disorders — e.g., Dravet syndrome (SCN1A), KCNQ2 epileptic encephalopathy
- Complex/multifactorial: Multiple variants + environment — e.g., common epilepsy, autism spectrum disorder; polygenic risk scores still limited in clinical use
- Mosaicism: Post-zygotic mutation producing two cell populations; severity correlates with proportion of affected cells; may cause focal cortical dysplasia or mosaic RASopathies
✦ Check Your Understanding
Which of the following best describes 'de novo' variants in the context of neurogenetic disease?
Select an answer to reveal the explanation
Common Neurogenetic Disease Categories
Neurogenetic diseases are conventionally grouped by clinical phenotype, although the same gene can cause multiple phenotypes (pleiotropy) and the same phenotype can result from variants in many genes (genetic heterogeneity). Knowing the most common neurogenetic disease categories and their prototypical genes equips clinicians to build focused differential diagnoses.
Key Points
- Epilepsies: SCN1A (Dravet), KCNQ2 (neonatal-onset EE), ALDH7A1 (pyridoxine-dependent), TSC1/TSC2 (tuberous sclerosis), CDKL5, FOXG1
- Intellectual disability / autism: FMR1 (Fragile X — most common inherited ID in males; protein product FMRP), MECP2 (Rett syndrome), SHANK3, ANKRD11 (KBG syndrome), 22q11.2 deletion, Down syndrome
- Movement disorders: HTT (Huntington), PRKN/PINK1/SNCA (Parkinson), ATXN1–3 (spinocerebellar ataxias), FXN (Friedreich ataxia), ATP1A3 (alternating hemiplegia)
- Neuromuscular: DMD (Duchenne MD), SMN1 (spinal muscular atrophy), DMPK (myotonic dystrophy), MFN2 (CMT2A), GJB1 (Connexin 32, CMT1X)
- Leukodystrophies / white matter disorders: ABCD1 (ALD), ARSA (MLD), GALC (Krabbe), EIF2B1–5 (VWM)
✦ Check Your Understanding
A child is found to have tuberous sclerosis complex (TSC) with subependymal nodules, ash-leaf macules, and focal epilepsy. The molecular cause is most likely:
Select an answer to reveal the explanation
The Neurogenetic History and Examination
The genetic evaluation begins with a structured history and examination tailored to identify patterns suggestive of an inherited or de novo neurological disorder. A three-generation pedigree is the cornerstone of genetic assessment and can often reveal the mode of inheritance before any test is ordered. Distinctive features, multi-system involvement, and characteristic neuroimaging patterns guide both the differential diagnosis and the choice of genetic test.
Key Points
- Three-generation pedigree: Document affected/unaffected status, age of onset, cause of death, consanguinity, and ethnicity for all first- and second-degree relatives
- Red flags for a genetic etiology: onset in childhood or adolescence, family history, intellectual disability/developmental delay, multiple organ involvement, distinctive features, response to dietary or vitamin therapies
- Examination pearls: search for subtle distinctive features (ear pits, hypertelorism, clinodactyly), skin findings (café-au-lait spots, ash-leaf macules, angiofibromas), and neurocutaneous stigmata
- Neuroimaging patterns that suggest specific genetic disorders: simplified gyral pattern (lissencephaly → LIS1, DCX), white matter signal abnormality (leukodystrophies), striatal necrosis (Leigh syndrome, mitochondrial disease), subependymal nodules (tuberous sclerosis)
✦ Check Your Understanding
When taking a family history for a child with suspected autosomal recessive neurogenetic disease, which pedigree feature is most informative?
Select an answer to reveal the explanation
Genetic Testing Strategies in Neurogenetics
The choice of genetic test should be guided by the clinical phenotype, suspected genetic architecture, and available resources. Modern sequencing has shifted practice toward comprehensive 'first-line' tests (chromosomal microarray, exome sequencing) in many settings, while targeted tests remain appropriate when the differential is narrow. Understanding test capabilities and limitations is essential for ordering the right test and interpreting results.
Key Points
- Chromosomal microarray (CMA): First-line for unexplained intellectual disability, autism, and multiple congenital anomalies; detects copy number variants ≥50–200 kb; does NOT detect single-nucleotide variants
- Gene panels: Targeted sequencing of 20–500 genes relevant to a phenotype (e.g., epilepsy panel, ataxia panel); higher sensitivity/specificity than exome for technically difficult regions; misses novel gene associations
- Exome sequencing (ES): Sequences all ~22,000 protein-coding genes; diagnostic yield ~30–40% for unsolved neurogenetic disorders; preferred when panel testing is non-diagnostic or phenotype is broad
- Genome sequencing (GS): Includes coding and non-coding regions; detects SNVs, indels, CNVs, and structural variants in one test; may screen for some short tandem repeat disorders; increasingly first-line in pediatric neurology
- Targeted tests: Trinucleotide repeat PCR (Huntington, Fragile X, Friedreich ataxia, myotonic dystrophy); methylation studies (Prader-Willi/Angelman); mitochondrial genome sequencing — order when specific diagnosis is suspected
✦ Check Your Understanding
Fragile X syndrome is the most common inherited cause of intellectual disability in males. What is its molecular mechanism?
Select an answer to reveal the explanation
0 of 5 sections read
Scroll through all sections to track your progress.